PMID- 17348868
OWN - NLM
STAT- MEDLINE
DCOM- 20070619
LR  - 20151119
IS  - 0042-9007 (Print)
IS  - 0042-9007 (Linking)
VI  - 92
IP  - 3
DP  - 2007 Apr
TI  - Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the 
      study of immunomodulation therapeutics.
PG  - 197-205
AB  - BACKGROUND AND OBJECTIVES: Intravenous immunoglobulin (IVIG) is used for an 
      increasingly diverse number of therapeutic applications as an immunomodulation 
      drug. Although it has demonstrated therapeutic effectiveness, the mechanism of 
      action of IVIG in these disorders is poorly understood; this lack of 
      understanding complicates rational clinical application and reimbursement for 
      'off-label' use. MATERIALS AND METHODS: Selected literature on the clinical use 
      of IVIG as an immunomodulation drug is reviewed. We present a brief description 
      of DNA microarray and protein microarray technology and the application of such 
      technologies to the study of immune system cells. The several studies on the 
      application of DNA microarray technology to study gene expression in response to 
      IVIG are presented. RESULTS: There is increasing data on the use of DNA 
      microarray and protein microarray technology to study gene expression in immune 
      system cells including T cells, B cells, macrophages, and leucocytes. There is 
      less information on the effect of IVIG on gene expression in immune system cells. 
      However, there is sufficient information available to suggest that this is a 
      practical approach with the caveat that such work will require careful 
      experimental design and clear definition of the normal population. CONCLUSIONS: 
      DNA and protein microarray assays can be used to (i) provide rational indications 
      for the clinical use of IVIG, (ii) provide for specific analysis of raw material 
      and end product IVIG in screening for content related to immunomodulation, and 
      (iii) accelerate the development of next generation products which would be more 
      focused and/or targeted therapeutics.
FAU - Sapan, C V
AU  - Sapan CV
AD  - Department of Pathology, University of North Carolina at Chapel Hill, Chapel 
      Hill, NC 27599, USA.
FAU - Reisner, H M
AU  - Reisner HM
FAU - Lundblad, R L
AU  - Lundblad RL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Vox Sang
JT  - Vox sanguinis
JID - 0413606
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Gene Expression Regulation/*immunology
MH  - Genomics
MH  - Humans
MH  - Immunoglobulins, Intravenous/pharmacology/*therapeutic use
MH  - Immunologic Factors/pharmacology/*therapeutic use
MH  - Oligonucleotide Array Sequence Analysis
MH  - Practice Patterns, Physicians'
MH  - Proteomics
RF  - 88
EDAT- 2007/03/14 09:00
MHDA- 2007/06/20 09:00
CRDT- 2007/03/14 09:00
PHST- 2007/03/14 09:00 [pubmed]
PHST- 2007/06/20 09:00 [medline]
PHST- 2007/03/14 09:00 [entrez]
AID - VOX877 [pii]
AID - 10.1111/j.1423-0410.2006.00877.x [doi]
PST - ppublish
SO  - Vox Sang. 2007 Apr;92(3):197-205. doi: 10.1111/j.1423-0410.2006.00877.x.